Halozyme Therapeutics HALO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's operating cash flow?
- Halozyme Therapeutics (HALO) reported operating cash flow of $180.08M in Q1 2026.
- How has Halozyme Therapeutics's operating cash flow changed year-over-year?
- Halozyme Therapeutics's operating cash flow increased by 16.8% year-over-year, from $154.22M to $180.08M.
- What is the long-term trend for Halozyme Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's operating cash flow has grown at a 21.5% compound annual growth rate (CAGR), from $299.44M to $651.56M.
- What does operating cash flow mean?
- The total cash generated from the company's day-to-day business operations.
- How do you interpret operating cash flow?
- Higher values indicate strong operational performance and the ability to self-fund growth.
- How does operating cash flow compare across companies?
- Universal metric; peers are compared based on the quality of earnings and cash conversion ratios.